Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism
Open Access
- 1 April 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 321 (1) , 389-399
- https://doi.org/10.1124/jpet.106.117580
Abstract
Methadone is administered as a racemate, although opioid activity resides in the R-enantiomer. Methadone disposition is stereoselective, with considerable unexplained variability in clearance and plasma R/S ratios. N-Demethylation of methadone in vitro is predominantly mediated by cytochrome P450 CYP3A4 and CYP2B6 and somewhat by CYP2C19. This investigation evaluated stereoselectivity, models, and kinetic parameters for methadone N-demethylation by recombinant CYP2B6, CYP3A4, and CYP2C19, and the potential for interactions between enantiomers during racemate metabolism. CYP2B6 metabolism was stereoselective. CYP2C19 was less active, and stereoselectivity was opposite that for CYP2B6. CYP3A4 was not stereoselective. With all three isoforms, enantiomer N-dealkylation rates in the racemate were lower than those of (R)-(6-dimethyamino-4,4-diphenyl-heptan-3-one) hydrochloride (R-methadone) or (S)-(6-dimethyamino-4,4-diphenyl-heptan-3-one) hydrochloride (S-methadone) alone, suggesting an enantiomeric interaction and mutual metabolic inhibition. For CYP2B6, the interaction between enantiomers was stereoselective, with S-methadone as a more potent inhibitor of R-methadone N-demethylation than R-of S-methadone. In contrast, enantiomer interactions were not stereoselective with CYP2C19 or CYP3A4. For all three cytochromes P450, methadone N-demethylation was best described by two-site enzyme models with competitive inhibition. There were minor model differences between cytochromes P450 to account for stereoselectivity of metabolism and enantiomeric interactions. Changes in plasma R/S methadone ratios observed after rifampin or troleandomycin pretreatment in humans in vivo were successfully predicted by CYP2B6- but not CYP3A4-catalyzed methadone N-demethylation. CYP2B6 is a predominant catalyst of stereoselective methadone metabolism in vitro. In vivo, CYP2B6 may be a major determinant of methadone metabolism and disposition, and CYP2B6 activity and stereoselective metabolic interactions may confer variability in methadone disposition.This publication has 66 references indexed in Scilit:
- Lipid Sulfates and Sulfonates Are Allosteric Competitive Inhibitors of the N-Terminal Phosphatase Activity of the Mammalian Soluble Epoxide HydrolaseBiochemistry, 2005
- EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISMDrug Metabolism and Disposition, 2004
- REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERSDrug Metabolism and Disposition, 2004
- Stereoselective metabolism of methadone N‐demethylation by cytochrome P4502B6 and 2C19Chirality, 2003
- Interindividual Variability of the Clinical Pharmacokinetics of MethadoneClinical Pharmacokinetics, 2002
- In Vitrotoin VivoExtrapolation for Trichloroethylene Metabolism in HumansToxicology and Applied Pharmacology, 1998
- Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N-Desmethyladinazolam in ManJournal of Pharmacy and Pharmacology, 1998
- Involvement of Cytochrome P450 3A4 Enzyme in the N-Demethylation of Methadone in Human Liver MicrosomesChemical Research in Toxicology, 1996
- Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarinChirality, 1991
- Estimation of methadone clearance: application in the management of cancer painPain, 1988